Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report

Yuji Yamashita; Yuko Tanaka; Seishi Kono; Meiko Nishimura; Toru Mukohara; Yukiko Morinaga; Shigeo Hara; Shintaro Takao

首页> 外文期刊>Breast care >Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report

【24h】

Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report

机译：帕妥珠单抗，曲妥珠单抗和多西他赛联合新辅助化疗对HER2阳性炎性乳腺癌的疗效：一例报告

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer.

机译：炎性乳腺癌（IBC）是原发性乳腺癌的最激进形式。

著录项

来源
《Breast care》 |2017年第1期|共页
作者
Yuji Yamashita; Yuko Tanaka; Seishi Kono; Meiko Nishimura; Toru Mukohara; Yukiko Morinaga; Shigeo Hara; Shintaro Takao;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类泌尿生殖器肿瘤;
关键词
Multidisciplinary treatmentInflammatory breast cancerCombination neoadjuvant chemotherapy;

机译：多学科治疗炎性乳腺癌联合新辅助化疗;

相似文献

外文文献
中文文献
专利

1. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [J] . Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, Breast Cancer Research . 2017,第1期

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗，曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛，帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌的新辅助治疗
2. COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN [J] . Colomer R., Ciruelos E., De la Haba J., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：HER2 +乳腺癌患者对Pertuzubab，曲妥珠单抗和多西他赛进行新辅助化疗的费用效用分析
3. ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL [J] . Ribeiro I, Lourenco O., Alves C., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：葡萄牙妥妥珠单抗联合曲妥珠单抗和多西他赛对葡萄牙HER2阳性，局部晚期，炎症或早期乳腺癌的新辅助治疗妇女的经济评价
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Effectiveness of Pertuzumab Trastuzumab and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report [O] . Yuji Yamashita, Yuko Tanaka, Seishi Kono, 2017

机译：帕妥珠单抗曲妥珠单抗和多西他赛联合新辅助化疗对HER2阳性炎性乳腺癌的疗效：一例报告
7. Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report [O] . Yuji Yamashita, Yuko Tanaka, Seishi Kono, 2017

机译：Hertuzumab，Trastuzumab和Docetaxel组合Neoadjuvant化疗对Her2阳性炎症乳腺癌的有效性：案例报告

Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report

摘要

著录项

相似文献

相关主题

期刊订阅